Skip to main content
Premium Trial:

Request an Annual Quote

OGT, Mergen Settle Microarray Patent-Infringement Suit

NEW YORK, Jan. 20 (GenomeWeb News) - Mergen and Oxford Gene Technology agreed on Jan. 13 to settle the patent-infringement litigation between them, according to Mergen spokesperson Jamie Love.

Under the terms of the deal, Sunnyvale, Calif.-based Mergen has purchased a license from Oxford, UK-based OGT allowing the company to manufacture and sell microarrays for investigating gene expression. Mergen has also dropped a countersuit as part of the deal.

Mergen spokesperson Love declined to disclose financial terms of the agreement.

Mergen sells the ExpressChip microarray.

The suit was one of several that OGT filed in the US District Court for the Northern District of Illinois in December 2002 to protect its broad US patent covering oligonucleotide arrays, according to GenomeWeb News' sister publication BioArray News.

Oxford Gene Technology manages the IP of microarray pioneer Edwin Southern, who jointly owns the patents with OxfordUniversity 

In mid-June, the company settled a similar suit it had filed in the same court, at the same time, against Motorola. That suit concerned Motorola's eSensor DNA Detection System.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.